Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Objective 8  

$1,380,376.00
Fiscal Year: 2008

Yellow dot: Objective has some degree of funding, but less than the recommended amount.4.8 Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014. IACC Recommended Budget: $22,200,000 over 5 years.

Download 2008 Question 4: Objective 8 projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Double masked placebo controlled trial of cholesterol in hypocholesterolemic ASD Tierney, Elaine Kennedy Krieger Institute
D-cycloserine in children and adolescents with autism Posey, David Indiana University-Purdue University Indianapolis
The pharmacognetics of treatment for insistence sameness in autism Owley, Thomas University of Illinois at Chicago
Aripiprazole in children and adolescents with autistic disorder McDougle, Christopher Indiana University-Purdue University Indianapolis
Risperidone and behavior therapy in children and adolescents with pervasive disorder McDougle, Christopher Indiana University-Purdue University Indianapolis
Understanding repetitive behavior in autism McCracken, James University of California, Los Angeles
Divalproex sodium ER in adult autism Hollander, Eric Mount Sinai School of Medicine
Double-blind placebo controlled trial of subcutaneous methyl B12 on behavioral and metabolic measures in children with autism Hendren, Robert University of California, Davis
A randomized, double blind, placebo controlled study of fatty acid supplementation in autism Carpenter, Laura Medical University of South Carolina
Neuronal nicotonic receptor modulation in the treatment of autism: A pilot trial of mecamylamine Arnold, L. Eugene The Ohio State University
Intransal oxytocin in the treatment of autism Anagnostou, Athanasius Mount Sinai School of Medicine
Oxytocin vs placebo on response inhibition & face processing in autism Anagnostou, Athanasius Mount Sinai School of Medicine

Objective Cumulative Funding Table

IACC Strategic Plan Objectives 2008 2009 2010 2011 2012 Total
Complete at least three randomized controlled trials on medications targeting core symptoms in people with ASD of all ages by 2014.

IACC Recommended Budget: $22,200,000 over 5 years
4.8
$1,380,376
12 projects

4.L.A
$1,168,146
10 projects

4.L.A
$1,924,932
11 projects

4.L.A
$1,527,858
12 projects

4.L.A
$3,713,783
14 projects

$9,715,095
4.L.A. Funding: The recommended budget was partially met.

Progress: 10-14 studies have been funded, which is more than the minimum recommended, and momentum within the pre-clinical phases of this objective is currently building. It should be noted, however, in that many of these studies are small trials or pilot studies. 

Remaining Gaps, Needs, and Opportunities: Though there is little evidence that CNS drug development in animals will translate to humans, either in terms of toxicity or efficacy, there is still a need for investment in well-established animal model studies to identify promising molecular, cellular, or systems targets before mounting randomized clinical trials in humans. However, existing drugs for other indications may be adapted to ASD without extensive pre-clinical work, and there is also evidence for proof of concept studies for ASD (particularly those addressing core symptoms). It is also critically important to develop appropriate outcome measures for use in trials.